The clinical relevance of the common ZEB1/YAP target gene set could be further validated by performing a meta-analysis for breast cancers conventionally classified as hormone receptor negative (ER−/PR−), which include the most aggressive subtypes48. Here, ZEB1 is linked to breast cancer.